S&P 500   3,957.75 (-0.15%)
DOW   33,698.07 (-0.25%)
QQQ   283.60 (-0.09%)
AAPL   142.06 (-0.41%)
MSFT   244.98 (-0.98%)
META   115.56 (+0.20%)
GOOGL   93.73 (+0.02%)
AMZN   89.40 (-1.05%)
TSLA   178.02 (+2.64%)
NVDA   172.96 (+0.74%)
NIO   13.06 (-2.61%)
BABA   92.97 (-1.27%)
AMD   69.35 (-1.59%)
T   19.24 (+0.63%)
MU   55.32 (+0.22%)
CGC   2.99 (-3.24%)
F   13.27 (+1.14%)
GE   82.31 (-1.58%)
DIS   93.59 (+1.12%)
AMC   6.02 (-0.82%)
PYPL   74.16 (-0.08%)
PFE   51.82 (+0.08%)
NFLX   324.02 (+4.43%)
S&P 500   3,957.75 (-0.15%)
DOW   33,698.07 (-0.25%)
QQQ   283.60 (-0.09%)
AAPL   142.06 (-0.41%)
MSFT   244.98 (-0.98%)
META   115.56 (+0.20%)
GOOGL   93.73 (+0.02%)
AMZN   89.40 (-1.05%)
TSLA   178.02 (+2.64%)
NVDA   172.96 (+0.74%)
NIO   13.06 (-2.61%)
BABA   92.97 (-1.27%)
AMD   69.35 (-1.59%)
T   19.24 (+0.63%)
MU   55.32 (+0.22%)
CGC   2.99 (-3.24%)
F   13.27 (+1.14%)
GE   82.31 (-1.58%)
DIS   93.59 (+1.12%)
AMC   6.02 (-0.82%)
PYPL   74.16 (-0.08%)
PFE   51.82 (+0.08%)
NFLX   324.02 (+4.43%)
S&P 500   3,957.75 (-0.15%)
DOW   33,698.07 (-0.25%)
QQQ   283.60 (-0.09%)
AAPL   142.06 (-0.41%)
MSFT   244.98 (-0.98%)
META   115.56 (+0.20%)
GOOGL   93.73 (+0.02%)
AMZN   89.40 (-1.05%)
TSLA   178.02 (+2.64%)
NVDA   172.96 (+0.74%)
NIO   13.06 (-2.61%)
BABA   92.97 (-1.27%)
AMD   69.35 (-1.59%)
T   19.24 (+0.63%)
MU   55.32 (+0.22%)
CGC   2.99 (-3.24%)
F   13.27 (+1.14%)
GE   82.31 (-1.58%)
DIS   93.59 (+1.12%)
AMC   6.02 (-0.82%)
PYPL   74.16 (-0.08%)
PFE   51.82 (+0.08%)
NFLX   324.02 (+4.43%)
S&P 500   3,957.75 (-0.15%)
DOW   33,698.07 (-0.25%)
QQQ   283.60 (-0.09%)
AAPL   142.06 (-0.41%)
MSFT   244.98 (-0.98%)
META   115.56 (+0.20%)
GOOGL   93.73 (+0.02%)
AMZN   89.40 (-1.05%)
TSLA   178.02 (+2.64%)
NVDA   172.96 (+0.74%)
NIO   13.06 (-2.61%)
BABA   92.97 (-1.27%)
AMD   69.35 (-1.59%)
T   19.24 (+0.63%)
MU   55.32 (+0.22%)
CGC   2.99 (-3.24%)
F   13.27 (+1.14%)
GE   82.31 (-1.58%)
DIS   93.59 (+1.12%)
AMC   6.02 (-0.82%)
PYPL   74.16 (-0.08%)
PFE   51.82 (+0.08%)
NFLX   324.02 (+4.43%)
NASDAQ:HALO

Halozyme Therapeutics - HALO Stock Forecast, Price & News

$57.94
+0.09 (+0.16%)
(As of 12/9/2022 10:14 AM ET)
Add
Compare
Today's Range
$57.43
$58.04
50-Day Range
$39.54
$59.44
52-Week Range
$31.36
$59.46
Volume
12,809 shs
Average Volume
1.31 million shs
Market Capitalization
$7.83 billion
P/E Ratio
38.89
Dividend Yield
N/A
Price Target
$57.88

Halozyme Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
0.1% Downside
$57.88 Price Target
Short Interest
Healthy
7.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.12mentions of Halozyme Therapeutics in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$2.48 M Sold Last Quarter
Proj. Earnings Growth
41.95%
From $2.05 to $2.91 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.90 out of 5 stars

Medical Sector

40th out of 1,022 stocks

Biological Products, Except Diagnostic Industry

4th out of 171 stocks

HALO stock logo

About Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Stock News Headlines

Where Halozyme Therapeutics Stands With Analysts
5 Analysts Have This to Say About Halozyme Therapeutics
LPCN: Focus on CNS Disorders
11 Best Diabetes Stocks To Buy Now
4 Analysts Have This to Say About Halozyme Therapeutics
Should You Hold Halozyme Therapeutics (HALO)?
Interview With Quoc Tran of Tran Capital
HALO Crosses Above Average Analyst Target
See More Headlines
Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Company Calendar

Last Earnings
11/02/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/28/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:HALO
CUSIP
40637H10
Employees
145
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$57.88
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
-0.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$402.71 million
Pretax Margin
40.12%

Debt

Sales & Book Value

Annual Sales
$443.31 million
Cash Flow
$2.01 per share
Book Value
$1.40 per share

Miscellaneous

Free Float
132,103,000
Market Cap
$7.83 billion
Optionable
Optionable
Beta
1.26

Social Links


Key Executives

  • Dr. Helen I. Torley M.B. Ch. B. (Age 59)
    M.R.C.P., Pres, CEO & Director
    Comp: $1.65M
  • Dr. Michael J. LaBarre Ph.D.Dr. Michael J. LaBarre Ph.D. (Age 58)
    Chief Technical Officer
    Comp: $779.55k
  • Ms. Nicole LaBrosse (Age 39)
    CFO & Director
  • Ms. Tram Bui
    VP of Investor Relations & Corp. Communications
  • Mr. Mark Snyder Esq.
    Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Ms. Amy Marinne Fox
    Chief HR Officer
  • Dr. Steve Knowles MBBS
    Chief Medical Officer
  • Mr. Todd Butler
    Chief of Staff to the CEO, VP & Head of Project Management
  • Dr. Christopher Bryant Ph.D. (Age 61)
    Chief Manufacturing Officer & Head of Technical Operations













HALO Stock - Frequently Asked Questions

Should I buy or sell Halozyme Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HALO shares.
View HALO analyst ratings
or view top-rated stocks.

What is Halozyme Therapeutics' stock price forecast for 2023?

7 Wall Street research analysts have issued 1-year price targets for Halozyme Therapeutics' stock. Their HALO share price forecasts range from $42.00 to $68.00. On average, they anticipate the company's stock price to reach $57.88 in the next year. This suggests a possible upside of 0.0% from the stock's current price.
View analysts price targets for HALO
or view top-rated stocks among Wall Street analysts.

How have HALO shares performed in 2022?

Halozyme Therapeutics' stock was trading at $40.21 at the start of the year. Since then, HALO shares have increased by 43.9% and is now trading at $57.85.
View the best growth stocks for 2022 here
.

When is Halozyme Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our HALO earnings forecast
.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $1.06. The biopharmaceutical company had revenue of $115.83 million for the quarter, compared to the consensus estimate of $101.94 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 134.71% and a net margin of 36.37%. During the same period last year, the firm earned $0.25 EPS.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics updated its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share (EPS) guidance of $2.10-$2.25 for the period, compared to the consensus earnings per share estimate of $2.04. The company issued revenue guidance of $655.00 million-$685.00 million, compared to the consensus revenue estimate of $661.33 million.

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.86%), Artisan Partners Limited Partnership (4.45%), Macquarie Group Ltd. (1.89%), Price T Rowe Associates Inc. MD (1.19%), Dimensional Fund Advisors LP (1.11%) and Eagle Asset Management Inc. (0.96%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley, Matthew L Posard, Michael J Labarre and Nicole Labrosse.
View institutional ownership trends
.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $57.85.

How much money does Halozyme Therapeutics make?

Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $7.82 billion and generates $443.31 million in revenue each year. The biopharmaceutical company earns $402.71 million in net income (profit) each year or $1.49 on an earnings per share basis.

How many employees does Halozyme Therapeutics have?

The company employs 145 workers across the globe.

Does Halozyme Therapeutics have any subsidiaries?
The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.
Read More
How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for the company is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at ir@halozyme.com, or via fax at 858-704-8311.

This page (NASDAQ:HALO) was last updated on 12/9/2022 by MarketBeat.com Staff